Clinical Trial Update: A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating apatinib plus tegafur gimeracil oteracil in recurrent/metastatic head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• tegafur gimeracil oteracil (tegafur gimeracil oteracil)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN